This is the latest in a long lineup of deals executed in the last two years as AstraZeneca struggles to overcome one of the weakest pipelines in the pharma industry.
4.50 /share is not enough for gale. Investors should be opposed to this.
it will take off when you least expect it.
GALE is no brainer.
2 years chart is a beauty.